A new part in the machine. This time, this is the conclusion of a British trial: hydroxychloroquine does not show "any beneficial effect" in treating patients with Covid-19. In the process, this clinical trial, called Recovery, announced the “immediate” cessation of the inclusion of new patients for this treatment.
Recovery, the first major clinical trial to deliver long-awaited results, was one of the only ones not to have suspended its tests on hydroxychloroquine after a controversial Lancet study , since withdrawn, which pointed to the ineffectiveness, even the damaging effect of the controversial molecule. After an analysis of the initial results, "we concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalized with Covid-19," the researchers said in a statement.
"Preliminary" results
"We therefore decided to stop recruiting participants for the hydroxychloroquine arm of the Recovery trial, with immediate effect," they added. They said they had decided to make these "preliminary results public because they have important consequences for patient care and public health".
Recovery is a randomized controlled clinical trial (patients chosen by lot), an experimental method considered to be the most solid for testing drugs. It is being conducted in the UK on more than 11,000 patients from 175 hospitals to assess the effectiveness of several treatments for Covid-19. Tests on the other treatment tracks continue.
No impact on mortality or hospitalization
The hydroxychloroquine part concerned 1,542 patients who received the molecule, compared to 3,132 patients who received standard care. The researchers conclude that there is no significant difference between the two groups either for the 28-day mortality or for the length of hospital stay.
"It is disappointing that this treatment is ineffective but it allows us to focus on the care and research on more promising drugs," said Peter Horby, the lead investigator.
While this treatment has been widely prescribed in many countries "in the absence of reliable information", "these results should change medical practice around the world and demonstrate the importance of large-scale randomized trials to allow taking decisions about the efficacy and safety of treatments, ”added his deputy Martin Landray.
World
Coronavirus: European study Discovery "plans" to resume testing on hydroxychloroquine
Health
Coronavirus: "I'm really sorry", the coordinator of the study of "The Lancet" on hydroxychloroquine apologizes
- Health
- Treatment
- Covid 19
- Coronavirus